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Introduction: Thyroid cancer can affect the quality of life of patients and no validated study has been 
conducted to evaluate the quality of life in patients with thyroid cancer in Iran. The purpose of this 
study was to evaluate the changes of quality of life in patients with thyroid cancer treated with 
radioactive iodine. 
Materials and Methods: According to a prospective longitudinal study, quality of life and mood in 
these patients were studied by two questionnaires: Short Form Health Survey (SF36) and Hospital 
Anxiety and Depression Scale (HADS) provided to the patients by the researcher. The questionnaires 
were completed one month before iodine injection, on the day of injection, at the end of the second 
week, and sixth month after radioactive iodine injection. The patients were treated in two groups of 
100 and 150 µ Curie. After completing the questionnaires, the resulting scores at four different time 
points were evaluated and compared. 
Results: The mean SF36 scores were lower than one month before iodine intake and after 6 months, 
the mean scores were lower than one month before iodine intake. The mean HADS scores one month 
after iodine intake were not significantly different from the time of iodine intake, but after two weeks, 
anxiety and depression were reduced, and the result continued till the sixth months. No difference was 
found in the levels of anxiety and depression between the doses of 100 and 150 µ Curie. 
Conclusion: The highest level of anxiety and depression and quality of life during the first two weeks 
of iodine intake reduced with time and iodine intake dose did not affect it. 
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Introduction 
The prevalence of thyroid cancer around the 
world is increasing (1) while mortality rate has 
been reduced and survival has been increased 
(2,3). The treatment and follow-up of patients 
with thyroid cancer has become a major 
challenge in the world. It can affect their 
quality of life significantly, and evaluating the 
quality of life in these patients can help 
improve post-treatment care (4,5). To date, 
few studies have been conducted on the effect 
of radiation therapy on the quality of life of 
these patients (6,7). Most studies have used 
general questionnaires to evaluate quality of 
life in patients with thyroid cancer who cannot 
evaluate the specific conditions of these 
patients and so far no acceptable tool has been 
available to measure quality of life in patients 
with thyroid cancer (8). Therefore, further 
studies are needed to investigate the effects of 
this disease and this treatment on one's quality 
of life. The harmful effects of thyroid cancer 
in addition to physical effects can affect the 
quality of life and mood of patients, which 
may be due both to the disease itself, the side 
effects and duration of treatment (9). So, it is 
important to know the changes in mood and 
function of patients and in their quality of life 
after radioactive iodine treatment (10) to 
improve the quality of life of patients with 
appropriate psychiatric measures. 
 
Materials and Methods 
This is a longitudinal prospective study. 150 
patients with Papillary and Follicular thyroid 
cancer entered the study referring to 
Endocrinology Clinic of Ayatollah Taleghani 
Hospital, Tehran, Iran, between 2017 and 
2018, who had 18 to 70 years of age, willing to 
participate and be treated with radioactive 
iodine at Nuclear Medicine Center of the same 
hospital. Serum TSH test was performed on 
patients before iodine intake, and one and six 
months after iodine intake. Patients completed 
SF36 and HADS questionnaires on four 
occasions: before iodine intake, at the time of 
intake, two weeks and six months thereafter.  
The checklist also included questions about 
variables (type, stage and size of thyroid 
tumor, pre-admission levothyroxine use, 
radioactive iodine dose, and etc.) and 




The method of repeated-measures analysis of 
variance was used to analyze the data, which is 
in fact a generalization of the paired t-test 
method (11). For the variable SF, 3 repeats 
were recorded that based on the analysis of 
variance Table, the test statistic value F is 
equal to 76.7 with a probability value of p-
value <0.001, so we conclude that a significant 
difference is found between the 3 repeats. 
Considering this significant difference, we 
identified significant differences between the 




The present study was performed on 150 
patients with thyroid cancer. The patients 
completed the two questionnaires SF36 and 
HADS at different stages. 
The results of this study are as follows. 
First, the mean SF scores were measured at 3 
time points. 
In order to determine whether these 
differences are significant, using Bonferroni 
method, the results of pairwise comparisons at 
3 times are obtained as following: 
 
These pairwise comparisons show that no 
significant difference is found between SF 
scores one month before iodine injection and 
at the time of iodine injection, but SF score six 
months after iodine injection was significantly 
lower than the time of iodine injection. Also, 
SF score six months after iodine injection was 
significantly lower than one month before 
iodine injection. The significant values 
corresponding to P-values less than 0.05 are 
shown in bold. 
For the variable HADS, 4 repeats have been 
recorded. According to the analysis of 
variance Table, F test statistic value is equal to 
80.6 with a probability value <0.001, so we 
conclude that a significant difference is found 
between the 4 repeats.  Considering this 
significant difference, we identified significant 
differences between the measured times using 
Bonferroni post hoc test. First, the mean 
HADS scores at the four measurement times 
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These values indicate that the mean HADS 
scores one month before iodine intake are 
approximately equal to the time of iodine 
intake, but two weeks after injection, the mean 
scores reduced, and after six months, this 
reduction is even greater. 
In order to determine whether these 
differences are significant, using Bonferroni 
method, the results of pairwise comparisons at 
4 times are obtained as follows: 
 
Study of these pairwise comparisons’ values 
indicated that no significant difference is 
found between HADS scores one month 
before iodine injection and at the time of 
iodine injection, but HADS score one month 
before iodine injection was significantly 
greater than two weeks after iodine injection, 
and HADS score one month before iodine 
injection is significantly higher than six 
months after iodine injection. In addition, 
HADS score at iodine injection was 
significantly higher than two weeks after 
iodine injection, and HADS score at iodine 
injection time was significantly higher than six 
months after iodine injection. Finally, HADS 
score two weeks after iodine injection was 
significantly higher than six months after 
iodine injection. The significant values 
corresponding to p-values less than 0.05 are 
indicated in bold. 
Given that only 3 cases of follicular cancer 
have been reported, it is in fact impossible to 
compare SF and HADS scores between the 
two types of cancer and no statistically 
significant difference was found. 
Independent t-test was used to compare two 
doses of the medicine according to their 
difference in HADS score two weeks and six 
months after iodine injection and the results 
were as following: 
 
P-value for the two values’ comparison is 
0.836, which means that the mean HADS 
score of the two doses of 100 and 150 did not 
differ significantly two weeks after injection. 
 
P-value for these two values’ comparison is 
0.594, which means that the mean HADS 
score of the two doses of 100 and 150 six 
months after injection is not significantly 
different. 
Independent t-test was used to compare two 
doses of the medicine according to their 
difference in SF score at the time of injection 
and six months after iodine injection and the 
results were as follows: 
 
The p-value for the two values’ comparison is 
0.304, which means that the mean SF scores of 
the two doses of 100 and 150 are not 
significantly different at the time of injection. 
 
P-value for the two values’ comparison is 
0.073, which means that the mean SF score of 
the two doses six months after injection is not 
significantly different. However, given p-value 
obtained between 0.05 and 0.1, this conclusion 
requires caution.  
At the time of injection, between HADS and 
SF scores, Pearson correlation coefficient was 
-0.57 (p-value <0.001), which means that an 
inverse and relatively strong and significant 
relationship is found. The corresponding graph 
of this relationship is displayed as follows: 
 
At the time of injection, Pearson's correlation 
coefficient was -0.66 between HADS and SF 
scores (p-value <0.001), which means that an 
inverse and relatively strong and significant 
relationship is found. The corresponding graph 
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Six months after injection, Pearson correlation 
coefficient was equal to 0.20 between HADS and 
SF scores (p-value = 0.018), which means that a 
direct and significant relationship is found. 
 
Discussion 
The present study was conducted to compare 
the symptoms of anxiety and depression and 
quality of life of patients with thyroid cancer 
who were treated with radioactive iodine at 
different times before, during and after 
radiation therapy in two doses of 100 and 150 
µ Curie. The present study was performed on 
150 patients, 3 of whom had follicular cancer 
and 147 had papillary cancer. Among them, 28 
patients were male (18.6%) and 122 patients 
were female (81.4%). The mean age was 43.2 
years. 
The results of our study showed that no 
significant difference was found between the 
mean and standard deviation of SF36 scores 
one month before iodine injection and at the 
time of iodine injection (2139.8 vs. 2203.9), 
but SF score six months after iodine injection 
was significantly lower than the time of iodine 
injection (1548 vs. 2203/9). Also, SF score six 
months after iodine injection was significantly 
lower than one month before iodine injection 
(1548 vs. 2139.8). 
The mean HADS scores one month before 
iodine intake were approximately equal to the 
time of iodine intake (12.9 vs. 13.4) but two 
weeks after injections, the mean scores 
reduced (10.7). After six months, the reduction 
was even greater (7.9). 
Study of these pairwise comparisons, values 
indicates that no significant difference is found 
between HADS scores one month before 
iodine injection and at the time iodine 
injection (12.9 vs. 13.4), but HADS scores one 
month before iodine injection was 
significantly greater than two weeks after 
iodine injection (12.9 vs. 10.7), and HADS 
score one month before iodine injection was 
significantly higher than six months after 
iodine injection (12.9 vs. 7.9). In addition, 
HADS score at iodine injection time was 
significantly higher than two weeks after 
iodine injection (13.4 vs. 10.7) and HADS 
score at iodine injection time was significantly 
higher than six months after iodine injection. 
(13.4 vs. 7.9). Finally, HADS score two weeks 
after iodine injection was significantly higher 
than six months after iodine injection (10.7 vs. 
7.9). 
Given that only 3 follicular cancer types were 
observed, it was virtually impossible to 
compare SF and HADS scores between the 
two types of cancer and no statistically 
significant difference was found. 
The mean HADS score of the two doses of 
100 and 150 two weeks after injection was not 
significantly different (10.5 vs. 10.3). P-value 
for the two values was 0.836. 
The mean HADS score of the two doses six 
months after injection was not significantly 
different (7.5 vs. 8). P-value for the two values 
was 0.594. 
The mean SF36 score of these two doses was 
not significantly different two weeks after 
injection (2137 vs. 2255). P-value for the two 
values was 0.304. 
The mean SF36 score of the two doses six 
months after injection was not significantly 
different (1430 vs. 1637). P-value for the two 
values was 0.073. 
 
Conclusion: 
The results of our study showed that mean 
SF36 scores one month before iodine intake 
were lower than the time of iodine intake, but 
after six months, the mean scores were lower 
than one month before iodine intake, 
indicating improved quality of life of patients 
6 months after iodine intake and mean HADS 
scores one month after iodine intake did not 
differ significantly from the time of iodine 
intake, but over time after two weeks anxiety 
and depression reduced significantly, which 
continued after six months, and patients' 
anxiety and depression symptoms were less 
than before. At doses of 100 and 150 µ Curie, 
no difference was found in anxiety and 
depression in two weeks and six months after 
iodine intake. 
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